NCT03751202View on ClinicalTrials.gov

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

December 11, 2018

Study Completion Date

December 11, 2018

Conditions

Bioequivalence

Interventions

DRUG

Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg

2 inhalations of Test and Reference product in each study period

DRUG

ADVAIR DISKUS

2 inhalations of Test and Reference product in each study period

Trial Locations (1)

41100

BECRO Clinical Facility, Larissa

All Listed Sponsors

collaborator

Becro Ltd.

INDUSTRY

lead

Respirent Pharmaceuticals Co Ltd.

INDUSTRY

NCT03751202 - A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers | Biotech Hunter | Biotech Hunter